Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

How do I Manage ILD/Pneumonitis with Verzenios® ▼ (abemaciclib) in Early Breast Cancer?

Persistent or recurrent Grade 2 toxicity was managed with dose suspension until toxicity resolved to baseline or Grade 1, while Grade 3 or 4 required discontinuation. Grade 1 or 2 did not require dose adjustment.

UK_cFAQ_ABE065_ILD_PNEUMONITIS_EBC
UK_cFAQ_ABE065_ILD_PNEUMONITIS_EBC
en-GB

Interstitial Lung Disease (ILD)/Pneumonitis Monitoring and Dose Modification

Dose modification and management are summarized in Management recommendations for ILD/pneumonitis.

ILD/pneumonitis was reported in patients receiving abemaciclib. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and treat as medically appropriate.1

Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.

Based on the severity of ILD/pneumonitis, abemaciclib may require dose modification. Permanently discontinue abemaciclib in patients with grade 3 or 4 ILD/pneumonitis.1

Management recommendations for ILD/pneumonitis1